<DOC>
	<DOCNO>NCT00476294</DOCNO>
	<brief_summary>Objectives : The objective long-term observational study assess progression-free survival overall survival period five year follow first dose study treatment ( placebo plerixafor [ AMD3100 ] ) protocol AMD3100-3102 . Patients receive least 1 dose study treatment ( placebo plerixafor ) multicenter , randomize , double-blind , placebo-controlled AMD3100-3102 study , design evaluate plerixafor plus granulocyte colony stimulate factor ( G-CSF ) versus placebo plus G-CSF mobilize hematopoietic stem cell autologous transplantation Multiple Myeloma ( MM ) patient eligible .</brief_summary>
	<brief_title>Long-Term Follow Up Study AMD3100 Patients</brief_title>
	<detailed_description>Informed Consent Process : Your study doctor staff either meet person contact phone review study information . You give copy consent form review ask question . If agree take part study , sign consent form date agree study . If agree take part phone call member study team , sign date form right away , date phone call , mail form study doctor staff . Please keep copy reference . 5-Year Follow-Up : You contact phone person visit , every 6 month 5 year time first study drug/placebo dose 2004-0982 study . A placebo substance look like study drug active ingredient . If receive transplant 2004-0982 study , first contact study either 18 month time begin 2004-0982 study , time sign consent form . If receive transplant , first contact study time sign consent form . At first visit call , ask status disease , change multiple myeloma may occur since 2004-0982 study , additional treatment may receive time . At every visit call , ask status multiple myeloma , change disease , treatment receive since last visit call . These questionnaire take 10 minute time . Your doctor study staff also may contact local doctor order collect information medical record information medical history disease status . Length Study Participation : You study last study phone call visit ( 5 year first study drug/placebo dose 2004-0982 study ) . This investigational study . Up 300 patient participate multi-center study . Up 12 enrol MD Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>1 ) All patient receive study drug ( placebo plerixafor ) protocol AMD31003102 ( 20040982 ) None</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Disease-Free Survival</keyword>
	<keyword>AMD3100</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Autologous Transplantation</keyword>
</DOC>